NVCR241220C27000
- 3.90
- 0.000.00%
Novocure Newsroom
NovoCure Shares Are Trading Higher After Piper Sandler Maintained an Overweight Rating on the Stock and Raised Its Price Target From $28 to $42.
Novocure Is Maintained at Overweight by Piper Sandler
NovoCure Analyst Ratings
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and NovoCure (NVCR)
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Why NovoCure Stock Was Winning Big This Week
Express News | Novocure Ltd : JP Morgan Raises Target Price to $29 From $19
A Quick Look at Today's Ratings for Novocure(NVCR.US), With a Forecast Between $30 to $40
Zai Lab, Novocure Announce PANOVA-3 Trial Met Primary Endpoint
U.S. Small Caps Close Mixed As Novocure Lead, Archer Aviation Lags
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates
Positive Outlook for NovoCure: Buy Rating Backed by Successful PANOVA-3 Trial and Promising Market Potential
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
NovoCure Up Over 30%, on Pace for Largest Percent Increase Since January 2023 -- Data Talk
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
US stocks fluctuate | Novocure surged about 42% at one point.
On December 2, Glonghui reported that medical devices manufacturer Novocure Ltd. (NVCR.US) initially surged about 42%, with the increase now narrowing to 26.8%, marking the largest intraday increase since January 2023. Recent research results indicate that the company's cancer treatment Tumor Treating Fields for pancreatic cancer has achieved its primary endpoint. (Glonghui)
Express News | Novocure Ltd : Wedbush Raises Target Price to $29 From $24